VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
1-Year Return
31.42%
This Quarter Return
-1.68%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$368M
AUM Growth
+$240M
(+188%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
64.25%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
777
New
414
Increased
42
Reduced
13
Closed
237
Top Buys
| 1 |
Virtus Newfleet ABS/MBS ETF
VABS
|
$32.2M |
| 2 |
Virtus Newfleet Short Duration High Yield Bond ETF
VSHY
|
$24.6M |
| 3 |
Virtus SEIX Senior Loan ETF
SEIX
|
$19M |
| 4 |
SMC
Summit Midstream Corporation
SMC
|
$3.67M |
| 5 |
OCCI
OFS Credit Co
OCCI
|
$2.41M |
Top Sells
| 1 |
ICICI Bank
IBN
|
$3.75M |
| 2 |
Virtus Duff & Phelps Clean Energy ETF
VCLN
|
$2.74M |
| 3 |
Apple
AAPL
|
$2.06M |
| 4 |
Microsoft
MSFT
|
$2.02M |
| 5 |
Primoris Services
PRIM
|
$1.86M |
Sector Composition
| 1 | Financials | 24.48% |
| 2 | Healthcare | 11.95% |
| 3 | Technology | 8.6% |
| 4 | Industrials | 8.02% |
| 5 | Energy | 4.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Nurix Therapeutics
NRIX
$758M
| $94.9K | 0.03% |
+7,986
| New | +$94.9K |
|
|
AUTL
427
Autolus Therapeutics
AUTL
$389M
| $94.6K | 0.03% |
+61,027
| New | +$94.6K |
|
428
Arrowhead Research
ARWR
$4.02B
| $94.5K | 0.03% |
+7,415
| New | +$94.5K |
|
429
Olema Pharmaceuticals
OLMA
$570M
| $91.8K | 0.03% |
+24,427
| New | +$91.8K |
|
430
Keros Therapeutics
KROS
$633M
| $90.8K | 0.02% |
+8,907
| New | +$90.8K |
|
431
Relay Therapeutics
RLAY
$710M
| $90K | 0.02% |
+34,345
| New | +$90K |
|
432
Structure Therapeutics
GPCR
$1.27B
| $89.6K | 0.02% |
+5,177
| New | +$89.6K |
|
433
Astria Therapeutics
ATXS
$424M
| $89.4K | 0.02% |
+16,735
| New | +$89.4K |
|
434
Stoke Therapeutics
STOK
$1.13B
| $88.6K | 0.02% |
+13,323
| New | +$88.6K |
|
435
Praxis Precision Medicines
PRAX
$986M
| $87.7K | 0.02% |
+2,316
| New | +$87.7K |
|
436
Vera Therapeutics
VERA
$1.54B
| $87.4K | 0.02% |
+3,637
| New | +$87.4K |
|
437
Rocket Pharmaceuticals
RCKT
$354M
| $87.1K | 0.02% |
+13,058
| New | +$87.1K |
|
|
RAPP
438
Rapport Therapeutics
RAPP
$524M
| $86.6K | 0.02% |
+8,637
| New | +$86.6K |
|
439
Neurogene
NGNE
$285M
| $86.1K | 0.02% |
+7,351
| New | +$86.1K |
|
440
Intellia Therapeutics
NTLA
$1.29B
| $86K | 0.02% |
+12,101
| New | +$86K |
|
441
Erasca
ERAS
$457M
| $85.5K | 0.02% |
+62,421
| New | +$85.5K |
|
442
Immunome
IMNM
$916M
| $84.5K | 0.02% |
+12,561
| New | +$84.5K |
|
443
Zentalis Pharmaceuticals
ZNTL
$126M
| $83.4K | 0.02% |
+52,449
| New | +$83.4K |
|
444
Viking Therapeutics
VKTX
$3.03B
| $82.8K | 0.02% |
+3,430
| New | +$82.8K |
|
445
Entrada Therapeutics
TRDA
$201M
| $81.9K | 0.02% |
+9,065
| New | +$81.9K |
|
446
Tango Therapeutics
TNGX
$772M
| $78.9K | 0.02% |
+57,599
| New | +$78.9K |
|
447
4D Molecular Therapeutics
FDMT
$340M
| $77.1K | 0.02% |
+23,864
| New | +$77.1K |
|
448
Arcus Biosciences
RCUS
$1.3B
| $75.1K | 0.02% |
+9,572
| New | +$75.1K |
|
449
Janux Therapeutics
JANX
$1.44B
| $72K | 0.02% |
+2,668
| New | +$72K |
|
450
Vaxcyte
PCVX
$4.29B
| $70.7K | 0.02% |
+1,872
| New | +$70.7K |
|